Earnings Release

L&T Technology Services and Emerson Announce Strategic Global Partnership for Engineering Innovation

NSE

ltts

BSE

540115

L&T Technology Services (LTTS) announced a strategic global partnership with Emerson to jointly develop advanced engineering solutions using Emerson’s NI test platform across industries including industrial automation, transportation, semiconductors, aerospace, and defense.

PRICE-SENSITIVE TRIGGER

Event: Strategic partnership announcement between LTTS and Emerson

Type: Earnings Release

Impact: Positive

Immediate Effect: The company delivered record operational and financial performance with strong profitability growth, improved liquidity, lower debtor days, and major expansion in hospital bed capacity.

Key Metrics:

Q4 FY26 Revenue: INR 4,604 million (+30% YoY)
Q4 FY26 EBITDA: INR 1,274 million (+44% YoY)
Q4 FY26 EBITDA Margin: 27.7% (+268 bps YoY)
Q4 FY26 Net Profit: INR 768 million (+47% YoY)
Q4 FY26 Net Profit Margin: 16.7% (+188 bps YoY)
Q4 FY26 EPS: INR 1.78 (+31% YoY)
FY26 Revenue: INR 16,794 million (+21% YoY)
FY26 EBITDA: INR 4,443 million (+20% YoY)
FY26 EBITDA Margin: 26.5%
FY26 Net Profit: INR 2,736 million (+27% YoY)
FY26 Net Profit Margin: 16.3% (+83 bps YoY)
FY26 EPS: INR 6.87 (+23% YoY)
Cash from Operations: INR 3,291 million
Fixed Deposits: INR 3,141 million
Total Cash & Cash Equivalents: INR 5,509 million
Term Debt: INR 282 million
Debtor Days Reduction: 161 days to 129 days

Highlight:

Highlight: FY26 Net Profit
Value: INR 2,736 million (+27% YoY)

What Happened ?

Park Medi World Limited announced audited standalone and consolidated financial results for Q4 and FY26, reporting the strongest annual performance in the company’s history.

The company achieved record revenue, EBITDA, and net profit while simultaneously executing its largest annual capacity expansion.

Management highlighted strong balance sheet improvement, increased liquidity, reduction in debtor days, and substantial expansion in hospital bed capacity through acquisitions and greenfield projects.

The company also announced significant ongoing and planned healthcare infrastructure expansion across North India.

key highlights

Financial and Operational Performance Highlights:

FY26 revenue reached a record INR 16,794 million, growing 21% YoY.
FY26 EBITDA increased 20% YoY to INR 4,443 million.
FY26 net profit rose 27% YoY to INR 2,736 million.
Q4 FY26 revenue grew 30% YoY to INR 4,604 million.
Q4 EBITDA margin expanded 268 basis points to 27.7%.
Q4 net profit margin improved to 16.7%.
Cash from operations stood at INR 3,291 million.
Debtor days reduced sharply from 161 days to 129 days.
Term debt remained negligible at INR 282 million.
The company maintained strong liquidity with INR 5,509 million in total cash and equivalents.
Bed capacity increased by 610 beds during FY26 through acquisitions in Bhatinda and Agra.
Greenfield hospital at Panchkula with 350 beds was commissioned in April 2026.
Acquisition of Febris Multi-Superspeciality Hospital in Narela, Delhi was completed.
Approval secured for 150-bed expansion at Mohali facility.
Total operational bed capacity increased to 3,610 beds by March 31, 2026 and further to 3,960 beds post Panchkula commissioning.

Note:

Management stated FY26 represented the strongest year in company history with simultaneous achievement of record profitability, balance sheet strengthening, and largest-ever annual capacity expansion.

Risk Analysis

Key Risks

Integration risks remain for recently acquired hospitals and facilities.
Large-scale expansion projects may temporarily pressure operational efficiency.
Healthcare staffing and specialist availability could impact margins.
Delays in commissioning newly acquired or expanded facilities may affect growth targets.
Healthcare regulatory changes and pricing controls remain industry-wide risks.
Sustaining high margins during rapid expansion may become challenging.

Worst Case Scenario

If integration and expansion execution face delays or utilization remains below expectations, profitability and return ratios could moderate in future periods.

Risk Level: Medium

Company Commentary

Management described FY26 as the finest year in Park Medi World’s history.
The company highlighted simultaneous growth in revenue, profitability, and balance sheet strength.
Management stated the company remains focused on disciplined capital allocation and measured expansion.
Park Medi World intends to improve utilization across newly acquired facilities.
The company reaffirmed commitment toward affordable, high-quality healthcare and long-term stakeholder value creation.

Official Exchange Filing: Park Medi World Limited